Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3247 - Impact of delayed addition of anti-EGFR monoclonal antibodies on the outcome of first-line therapy in metastatic colorectal cancer patients: a retrospective registry-based analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Targeted Therapy;  Colon and Rectal Cancer

Presenters

Tomas Buchler

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Buchler1, O. Fiala2, V. Veskrnova3, R. Chloupkova4, A. Poprach5, I. Kiss5, K. Kopeckova6, L. Dusek4, L. Slavicek7, M. Kohoutek8, J. Finek9, M. Svoboda5, J. Dvorak3, L.B. Petruzelka10, B. Melichar11

Author affiliations

  • 1 Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, 140 59 - Prague/CZ
  • 2 Oncology, University Hospital Plzen, 30460 - Plzen/CZ
  • 3 Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, 140 59 - Prague/CZ
  • 4 Institute Of Biostatistic And Analyses, Masaryk University Brno, 62500 - Brno/CZ
  • 5 Department Of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 65653 - Brno/CZ
  • 6 Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, 15006 - Prague/CZ
  • 7 Oncology, Hospital Jihlava, 58633 - Jihlava/CZ
  • 8 Oncology, T Bata's Regional Hospital, 762 75 - Zlin/CZ
  • 9 Oncology, University Hospital Plzen, 30133 - Plzen/CZ
  • 10 Oncology, First Faculty of Medicine, Charles University and General University Hospital, 128 08 - Prague/CZ
  • 11 Oncology, Palacky University Medical School and Teaching Hospital, 77520 - Olomouc/CZ
More

Resources

Abstract 3247

Background

The addition of monoclonal antibodies against epidermal growth factor receptor (anti-EGFR Abs) to chemotherapy is commonly delayed in the real-world clinical practice, usually because of delays in obtaining RAS testing results. The aim of this retrospective registry-based analysis was to determine whether the delayed addition of anti-EGFR mAbs up to the fourth cycle of backbone chemotherapy adversely affects outcomes of mCRC patients treated with first-line regimens.

Methods

Clinical data of patients with RAS wild-type mCRC treated with first-line systemic therapy regimens containing anti-EGFR mAbs from a national database were analysed retrospectively. Patients were divided into three groups according to the timing of anti-EGFR mAbs addition to the chemotherapy backbone. Cohort A (n = 401) included patients with anti-EGFR mAbs added to chemotherapy from the first cycle, cohort B (n = 71) patients with anti-EGFR mAbs added to chemotherapy from the second cycle, and cohort C (n = 101) patients who had anti-EGFR mAbs added to chemotherapy from the third or fourth cycle. The chemotherapy backbone regimens consisted of FOLFOX or FOLFIRI regimens.

Results

336 (58.6%) patients received panitumumab and 237 (41.4%) patients received cetuximab. The median progression-free survival (PFS) of the whole cohort was 12.2 months (95% confidence interval [CI] 10.9–13.5), and the median overall survival (OS) was 33.5 months (95% CI 27.6–39.4). Survival results for the cohorts defined by the time of addition of anti-EGFR MoAbs to chemotherapy are shown in the table. In a multivariate test, ECOG performance status and chemotherapy regimen were associated with PFS, whereas the site of primary tumour and chemotherapy regimen were associated with OS.Table: 491P

CohortPFS (95% CI), monthsLog-rank p-valueOS (95% CI), monthsLog-rank p-value
A (n = 401)12.9 (11.5–14.3)30.6 months (25.2–36.1)
B (n = 71)9.7 (9.1–10.3)A vs. B p = 0.185Not reachedA vs. B p = 0.645
C (n = 101)11.5 (9.8–13.2)A vs. C p = 0.82637.9 months (28.6–47.3)A vs. C p = 0.052

Conclusions

Delayed addition of anti-EGFR mAbs up to the fourth cycle of first-line chemotherapy was not associated with inferior survival or response rates.

Clinical trial identification

Legal entity responsible for the study

Tomas Buchler.

Funding

The institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno received financial support for the CORECT registry from Bayer, Amgen, Merck, and Roche.

Editorial Acknowledgement

Disclosure

T. Buchler, O. Fiala: Research funding, Travel grants, honoraria: Roche, Merck, Bayer, Servier, BMS, MSD, Sanofi, Amgen. A. Poprach: Honoraria, travel grants: Roche, Amgen. I. Kiss: Speakers’ honoraria: Roche, Merck, Amgen. J. Finek: Lecture honoraria, travel grants: Roche, Merck, Pfizer, Novartis, Amgen. B. Melichar: Research funding, travel grants, Honoraria: Roche, Merck, Bayer, Servier, BMS, MSD, Sanofi, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.